Concepedia

Robert Hettle

RH

17

Publications

541

Citations

12

H-Index

2011

Active since

Affiliations

AstraZeneca (United Kingdom)(Current)

PAREXEL International (United Kingdom)

University of Oklahoma

AstraZeneca (United States)

Oklahoma State University Oklahoma City

Robert Hettle is an author at AstraZeneca (United Kingdom) specializing in medicine, oncology, and outcomes research.

ORCID

Top concepts

Publications per year

2011–2021

17

Publications

17

The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal

Robert Hettle, Mark Corbett, Sebastian Hinde et al. · Health Technology Assessment · 2017 · 120 citations · Full text

Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial

Mark E. Robson, Kathryn J. Ruddy, Seock‐Ah Im et al. · European Journal of Cancer · 2019 · 84 citations · Full text

Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial

Michael Friedländer, Kathleen N. Moore, Nicoletta Colombo et al. · The Lancet Oncology · 2021 · 54 citations

, , +10

Cost-Effectiveness of Adding Bedaquiline to Drug Regimens for the Treatment of Multidrug-Resistant Tuberculosis in the UK

Lara J. Wolfson, Anna N. Walker, Robert Hettle et al. · PLoS ONE · 2015 · 47 citations · Full text

Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England

Robert Hettle, Gerard Harty, Schiffon L. Wong · Journal of Medical Economics · 2018 · 38 citations · Full text

Rows per page

1–5 of 17